Azathioprine: When less is more

2002; 46: 2525–32. 10 Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004; 48: 3498–507. 11 Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 2007; 51: 902–11. 12 Colonno R, Rose R, Pokornowski K et al. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. J. Hepatol. 2007; 46 (Suppl. 1): S294. 13 Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445–51. 14 Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385–91. 15 Chen CH, Wang JH, Lee CM et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir. Ther. 2006; 11: 771–8. 16 Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414–9. 17 van Bommel F, Zollner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318–25. 18 Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576–88. 19 Han SH, Lai CL, Gane E et al. Telbivudine GLOBE Trial at Year Two: Efficacy, Safety, and Predictors of Outcome in Patients with Chronic Hepatitis B. Gastroenterology 2007; 132: A–765. [S1777].

[1]  J. Sanderson,et al.  Influence of xanthine oxidase on thiopurine metabolism in Crohn’s disease , 2008, Alimentary pharmacology & therapeutics.

[2]  A. Andoh,et al.  Monitoring 6‐thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease , 2008, Journal of gastroenterology and hepatology.

[3]  S. Brant,et al.  500 Inherent Differences in 6mp Transport in Human Lymphocytes: Correlation with Drug-Induced Cytotoxicity , 2008 .

[4]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  U. Klotz,et al.  Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.

[6]  U. Klotz,et al.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. , 2007, Clinical pharmacokinetics.

[7]  C. Lewis,et al.  Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. , 2005, Clinical chemistry.

[8]  T. Florin,et al.  Thiopurine Therapies: Problems, Complexities, and Progress With Monitoring Thioguanine Nucleotides , 2005, Therapeutic drug monitoring.

[9]  B. Scott,et al.  How effective are the usual treatments for Crohn's disease? , 2004, Alimentary pharmacology & therapeutics.

[10]  T. Iga,et al.  Frequency Distribution of Thiopurine S-Methyltransferase Activity in Red Blood Cells of a Healthy Japanese Population , 2004, Therapeutic drug monitoring.

[11]  H. Togari,et al.  A Japanese case with inosine triphosphate pyrophosphohydrolase deficiency attributable to an enzymatic defect in white blood cells , 2004, Journal of Inherited Metabolic Disease.

[12]  H. Ogata,et al.  Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. , 2003, Journal of gastroenterology.

[13]  T. Florin,et al.  6‐thioguanine: a new old drug to procure remission in inflammatory bowel disease , 2003, Internal medicine journal.

[14]  E. Seidman.  Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. , 2003, Reviews in gastroenterological disorders.

[15]  C Hassan,et al.  Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease , 2002, Alimentary pharmacology & therapeutics.

[16]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[17]  H. Simmonds,et al.  Fast and slow methylators: do racial differences influence risk of allograft rejections? , 1993 .

[18]  H. Simmonds,et al.  Fast and slow methylators: do racial differences influence risk of allograft rejection? , 1993, The Quarterly journal of medicine.

[19]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.